Preclinical data of tasquinimod in myelofibrosis to be presented at ASH 2024
Lund, November 5, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that an abstract with preclinical data for tasquinimod in myelofibrosis has been accepted for presentation at the 66th American Society of Hematology Annual Meeting in San Diego, December 7-10, 2024 (ASH 2024). The abstract demonstrating efficacy of tasquinimod in experimental models of myelofibrosis will be presented as a poster. The accepted abstracts for ASH 2024 were published today, November 5, 2024.
The abstract, entitled Evaluation of the lethal activity and its mechanism of tasquinimod in advanced myeloproliferative neoplasm (MPN) in blastic phase, will be presented as a poster by Dr. Warren Fiskus, PhD, MD Anderson Cancer Center, Texas, USA. The abstract is a result of the collaboration between Active Biotech and Professor Kapil Bhalla´s research group at MD Anderson, and aims to support the clinical development of tasquinimod in myelofibrosis. Data to be presented add further insights to the potential of tasquinimod in combination with new therapies in models of advanced myelofibrosis. It also show that tasquinimod increases the lethality of disease cells in cellular models of late-stage myelofibrosis in blastic phase.
“The data to be presented suggest that treatment with tasquinimod holds the potential to have a broad effect on late-stage myelofibrosis both given as monotherapy and in combination with other treatments,” said Marie Törngren, VP R&D at Active Biotech.
“We are honored to have the opportunity to collaborate with MD Anderson, both in the preclinical stage with Professor Kapil Bhalla and his team, as well as the ongoing clinical study with tasquinimod in patients with late-stage myelofibrosis,” said Helén Tuvesson, CEO of Active Biotech.
Information on the presentations:
Publication Number: 3142 Evaluation of the lethal activity and its mechanism of tasquinimod in advanced myeloproliferative neoplasm (MPN) in blastic phase, Warren Fiskus et al.
Session Name: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II
Session Date: Sunday, December 8, 2024
Presentation Time: 6:00 PM – 8:00 PM (local time)
Location: San Diego Convention Center, Halls G-H
The abstracts will be available online on ASH’s website from 09:00 Eastern time (15:00 CET) on November 5, 2024.